Menu
Recruiting NCT06368700

The HYALEX Pivotal Study

No phase Interventional Damaged Chondral or Osteochondral Area

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Hyalex Knee Cartilage System.
Who it may be relevant to
Registry conditions: Damaged Chondral or Osteochondral Area. Basic parameters: 22 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The HYALEX Freestyle™ Resurfacing System Pivotal Study: A Multicenter, Single-Arm, Pivotal Study of the HYALEX Freestyle Resurfacing Implant

Overview

A multicenter, open-label, single-arm, pivotal study to evaluate the safety and effectiveness of the HYALEX Freestyle Resurfacing System for replacement of loss of articular cartilage and bone of the knee femoral condyles in symptomatic patients who require surgical treatment, will be enrolled in the study and undergo implantation of the HYALEX Freestyle Resurfacing Implant.

Interventions

  • Device Hyalex Knee Cartilage System
    Surgical implantation of the Hyalex Knee Cartilage System

Primary outcome measures

  • Composite Primary Endpoint [Time frame: 12 months]
  • Change in the Knee Injury & Osteoarthritis Outcome Score (KOOS) at 12 months. [Time frame: 12 months]

Eligibility criteria

Inclusion Criteria (Phase 1):

  • 22-70 years.
  • Body Mass Index (BMI) ≤ 40.
  • Up to two treatable joint surface lesion, ICRS Grade 3 or 4, located on the medial and/or lateral femoral condyle.
  • Up to 2 implants (one implant per condyle) to treat up to 2 individual symptomatic lesions with a total summative area up to 4.52cm2 / condyle.
  • Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale score between 20 and 65.
  • Ligamentously stable knee.
  • Failure of non-operative treatment (e.g., physical therapy, physician-directed at home exercise program, intra-articular injections, bracing) for at least 4 months prior to consideration for participation in the study.

Exclusion criteria

HYALEX Implant, Surgical Technique, and Lesion Site Exclusions:

  • Known allergy to polyurethanes, bone cement, acrylic, or titanium.
  • Lack of 2mm of cartilage (ICRS Grade 0 to 2) and 2mm of vital bone wall on all sides of the implant site.
  • Osteochondral defect affecting subchondral bone more than 11mm in depth from adjacent non-defect articular surface.
  • Bipolar cartilage lesions involving patellar or tibial lesions ICRS Grade 3 - 4 opposite the lesion intended for treatment.
  • Insufficient bone stock or bone density determined intra-operatively preventing implant press fit.

Patient Orthopaedic Health Exclusions:

  • Kellgren and Lawrence (KL) grade 3 or 4 on standing radiographs.
  • Hip-knee-ankle (HKA) angle of greater than +/- 8 degrees (varus or valgus malalignment > 8 degrees) on standing X-ray.
  • Lack of normally functioning contralateral knee that restricts activity.
  • Recent Osteochondritis Dissecans within 1 year.
  • Diagnosis of a concomitant knee injury which the investigator believes may interfere with study participation or confound effectiveness assessment.
  • Untreated ACL and/or PCL deficiency or complex ligamentous instability of the study knee according to IKDC Grade C (abnormal) or D (severely abnormal).

Previous Surgery and Intervention Exclusions:

  • Previous surgical cartilage treatment in the index knee within the last 6 months
  • Previous intra-articular injections, including HA and steroids, within the last 3 months prior to the date of surgery.

Patient Overall Health and Health History Exclusions:

  • Any known history of inflammatory arthropathy or untreated or uncontrolled crystal-deposition arthropathy.
  • Current cigarette smoker or user of other nicotine products.
  • Known Type 1 or Type 2 insulin-dependent diabetes mellitus.
  • Currently undergoing immunosuppressive therapy or long-term steroid use (corticosteroid, excluding inhalers) or within 3 months prior to surgery.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 4 centers
  • Horizon Clinical Research — La Mesa
  • Ochsner Sports Medicine Institute — New Orleans
  • Hospital for Special Surgery — New York
  • Oregon Health & Science University — Portland

Identifiers

NCT: NCT06368700 · CL-00001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗